Overview

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.

Phase:

PHASE2

Details

Lead Sponsor:

Protalix

Treatments:

Methotrexate